Quince Therapeutics (NASDAQ:QNCX) Raised to “Outperform” at Citizens Jmp

Quince Therapeutics (NASDAQ:QNCX – Get Free Report) was upgraded by equities researchers at Citizens Jmp from a “market perform” rating to an “outperform” rating in a research report issued on Tuesday, MarketBeat reports. The firm currently has a $77.00 target price on the stock. Citizens Jmp’s target price would indicate a potential upside of 148.39% from the stock’s previous close.

A number of other brokerages have also weighed in on QNCX. Wall Street Zen lowered Quince Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 22nd. Weiss Ratings downgraded Quince Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, August 26th. Cantor Fitzgerald restated an “overweight” rating and set a $70.00 target price on shares of Quince Therapeutics in a research report on Tuesday, August 18th. Zacks Research raised shares of Quince Therapeutics to a “hold” rating in a research note on Wednesday, June 24th. Finally, Craig Hallum upgraded shares of Quince Therapeutics to a “strong-buy” rating in a report on Thursday, August 27th. Two analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $229.50.

Get Quince Therapeutics alerts:

View Our Latest Report on QNCX

Quince Therapeutics Trading Up 5.2%

Shares of QNCX opened at $31.00 on Tuesday. Quince Therapeutics has a twelve month low of $15.10 and a twelve month high of $909.98. The stock’s 50 day moving average is $27.71 and its two-hundred day moving average is $23.77. The firm has a market capitalization of $31.62 million, a PE ratio of -0.20 and a beta of 1.31.

Quince Therapeutics (NASDAQ:QNCX – Get Free Report) last issued its earnings results on Friday, August 14th. The company reported ($12.31) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($28.02) by $15.71.

Hedge Funds Weigh In On Quince Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. acquired a new stake in shares of Quince Therapeutics during the 2nd quarter worth about $31,000. 683 Capital Management LLC acquired a new position in shares of Quince Therapeutics in the fourth quarter valued at approximately $798,000. Finally, Intellectus Partners LLC purchased a new position in shares of Quince Therapeutics during the fourth quarter valued at approximately $179,000. Institutional investors and hedge funds own 30.75% of the company’s stock.

About Quince Therapeutics

(Get Free Report)

Quince Therapeutics, Inc is a clinical-stage biotechnology company focused on developing treatments for rare diseases. The company’s research centers on its erythrocyte-derived extracellular vesicle (EEV) platform, which uses patients’ red blood cells to encapsulate and deliver therapeutic compounds.

Quince’s lead investigational product is eDSP, formerly known as EryDex, an autologous red-blood-cell-based formulation of dexamethasone sodium phosphate being developed for ataxia-telangiectasia (A-T).

Read More

• Five stocks we like better than Quince Therapeutics
• Despite Record Sales, Texas Roadhouse Has Beef With Beef Costs
• Nucor and Steel Dynamics Just Pulled Back—The Steel Story Still Looks Strong
• Amazon’s $8 Billion Generac Deal Shows AI’s New Power Bottleneck
• Can Bloom Energy Pop the Top Off AI’s Massive Energy Bottleneck?

Receive News & Ratings for Quince Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quince Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.